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Abstract:  
Epithelial-to-mesenchymal transition (EMT) is critical for embryonic development and 
wound healing, and occurs in fibrotic disease and carcinoma. Here, we show that EMT also 
occurs within the bulge, the epithelial stem cell (eSC) niche of human scalp hair follicles 
(HFs), during the inflammatory permanent alopecia, lichen planopilaris (LPP).  
We show for the first time that a molecular EMT signature can be experimentally induced in 
healthy human eSCs in situ by antagonizing E-cadherin, combined with TGF-ß1, EGF, and 
interferon- administration. Moreover, induction of EMT within primary human eSCs can be 
prevented and even partially reversed ex vivo by PPAR- agonists, likely through suppression 
of TGF signaling pathway.  Furthermore, we show that PPAR- agonism also attenuates the  
EMT signature even in lesional LPP HFs ex vivo.   
Thus, we introduce LPP as a model disease for pathological EMT in human adult eSCs, 
report the first preclinical assay for therapeutically manipulating eSC EMT within a healthy 
human (mini-)organ and show that PPAR- agonists are promising agents for suppressing and 
partially reversing EMT in human HF eSCs ex vivo, including in LPP. 
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Introduction 
 
Epithelial-to-mesenchymal transition (EMT) is a physiological feature during embryogenesis 
and wound healing, but also occurs during pathological phenomena such as the malignant 
transformation of epithelial cells, carcinoma metastasis, and several fibrotic diseases (Nieto et 
al., 2016, Stone et al., 2016). During EMT, epithelial cells gradually assume a fibroblast-like 
morphology as a result of transcriptional repression of E-cadherin via E-box binding factors, 
such as SNAI1 (SNAIL), SNAI2 (SLUG) and TWIST, and upregulation of mesenchymal 
hallmark proteins such as vimentin and fibronectin (Nieto et al., 2016, Zeisberg and Neilson, 
2009).  
EMT is frequently investigated using immortalised cell lines that display an abnormal 
karyotype and epigenetic modifications not observed in normal cells (Serrano-Gomez et al., 
2016). Primary cells are also utilised, even though these often adopt a wound healing-like 
spontaneous EMT response when cultured in vitro (Nieto et al., 2016, Stone et al., 2016). 
Therefore, the cellular behavior under these artificial conditions might not accurately reflect 
EMT as it occurs in vivo. Moreover, while existing animal models for studying EMT in vivo 
provide a native tissue environment, it is unclear how well these mimic human EMT under 
physiological or pathological conditions, or predict whether experimental therapies will 
translate to the clinic (Pasquier et al., 2015). This caveat is particularly relevant in the skin, 
given the many anatomical and functional differences between rodent and human skin. 
Finally, though EMT events can be studied, in patient biopsies, these typically catch only the 
final stages in the stepwise and initially reversible EMT continuum (Nieto et al., 2016, 
Pasquier et al., 2015, Serrano-Gomez et al., 2016, Stone et al., 2016, Zeisberg and Neilson, 
2009). 
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Therefore, clinically relevant models are urgently needed that permit one to study EMT 
initiation within human tissue in situ. Namely, it remains unknown whether adult epithelial 
stem cells (eSCs) undergo EMT in human skin and how this may relate to fibrotic skin 
diseases. Human hair follicles (HFs) are a repository for eSCs (Purba et al., 2014) and show 
scarring hair loss (alopecia) when these eSCs get destroyed within their immunologically 
privileged niche, the bulge (Harries et al., 2013, Harries and Paus, 2010). Therefore, we 
aimed to explore whether human scalp HFs can serve as an instructive model system for 
studying the EMT process in eSCs in live human tissue.   
For this, we focused on lichen planopilaris (LPP), one of the most frequently encountered 
primary cicatrial alopecias (PCA), a group of relatively rare, but clinically important 
inflammatory alopecias that result in skin scarring and permanent hair loss (Harries and Paus, 
2010, Sinclair, 2016).  While current evidence suggests that LPP results from a CD8+ T cell-
driven attack on eSCs that have lost their relative immune privilege (Harries et al., 2013) the 
loss of eSCs alone does not explain the typically associated scarring. Indeed, when K15+ve 
bulge eSCs were selectively deleted in mice, the resulting alopecia was not accompanied by 
scarring (Ito et al., 2005). However, abnormal expression of Snail has been identified in the 
fibrotic dermis of frontal fibrosing alopecia, another variant of PCA (Nakamura and Tokura, 
2010), inviting the hypothesis that EMT may play a role in PCAs (Nakamura and Tokura, 
2011).  
Therefore, we have probed the working hypothesis that eSCs in the HF bulge undergo EMT 
in LPP and that this process may be experimentally induced even in healthy human bulge 
eSC ex vivo, if exposed to appropriate EMT-promoting stimuli. If confirmed, such an ex vivo 
assay should provide an excellent, clinically relevant model system for dissecting the as yet 
unclear molecular controls of human eSC EMT in situ, and for identifying candidate drugs 
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that counteract eSC EMT under clinically relevant conditions. Here, we provide evidence in 
support of this working hypothesis by examining lesional LPP skin in situ and organ-cultured 
healthy human scalp HFs ex vivo.  
 
 
 
 
Results and Discussion 
 
Lesional LPP hair follicles display morphological and ultrastructural signs of EMT 
within their epithelial stem cell niche  
First, we re-examined our archive of LPP patient samples (Harries et al., 2013) and 
complemented this with biopsy material from additional LPP patients. Morphological 
analysis of the bulge compartment of lesional LPP HFs (as indicated by the arrector pili 
muscle insertion point (Figure 1A) and other previously defined human bulge markers 
(Purba et al., 2014) revealed a breakdown of the usual, very tight segregation between the 
eSC compartment and the surrounding HF mesenchyme in lesional LPP HFs; occasionally 
even the highly pathological presence of spindled cells of myofibroblast-like appearance 
could be demonstrated within the bulge epithelium itself (Figure 1B).  
These findings were followed-up by transmission electron microscopy. This confirmed the 
presence of fibroblastoid cells within lesional bulge epithelium and revealed putative 
collagen filaments within the cytoplasm of bulge keratinocytes (Figure 1C), a pathological 
ultrastructural phenomenon previously reported during EMT of ocular epithelium (Ogawa et 
al., 2009).  
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LPP bulge epithelium shows an mRNA and protein signature compatible with the 
occurrence of EMT 
Next, we searched for aberrant expression of EMT-associated mRNA species in lesional 
bulge epithelium compared to non-lesion bulge areas from the same individual by 
quantitative real-time PCR (qRT-PCR was performed on mRNA that had previously been 
selectively obtained from the bulge by laser capture microdissection (Harries et al., 2013)). 
This approach elucidated the expression of several EMT related genes in some of our LPP 
lesional biopsies, with no detectable expression in any healthy biopsy from the same patients. 
This was the case for TWIST1 (2/6 patients), ZEB2 (3/6), FN1 (fibronectin; 4/6), ACTA2 (α-
smooth muscle actin; 4/6), EMP1 (3/6) (Supplemental Table 1). Other EMT related 
transcripts were found in both the LPP lesional and healthy bulge, such as CD44 
(Supplemental Table 1), which is a known epithelial bulge marker (Szabo et al., 2013). 
More surprising was the presence of SNAI2 and ZEB1, which might indicate that some 
(presumably reversible) EMT occurs long before clinical presentation. We did not observe an 
EMT signature in every single donor and this may reflect the severity of disease, or the 
transient nature of EMT. However, the fact that we sometimes detect EMT markers in LPP 
lesional bulge, but never from an unaffected region from the same donor, adds weight to our 
hypothesis.  
 
To more fully explore this, we assessed the protein expression of key EMT markers within 
the bulge of lesional LPP HFs compared to scalp from healthy volunteers via quantitative 
immunohistomorphometry (Harries et al., 2013) (Figure 1D and Supplemental Figure 1). 
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This showed E-cadherin protein expression in the bulge of lesional LPP HFs to be 
significantly reduced, while the number of vimentin+ or fibronectin+ cells was significantly 
increased. When we also investigated the protein expression of early EMT markers, SNAIL 
protein-positive cells were significantly increased in the bulge epithelium of LPP, 
predominantly showing the expected nuclear immunoreactivity (Dubois-Marshall et al., 
2011) (Supplemental Figure 1). Moreover, SLUG protein immunoreactivity was also 
significantly increased in LPP HFs, while a trend towards increased expression of TWIST 
protein was also observed (Figure 1C). Interestingly, SLUG protein was expressed 
predominantly within the cytoplasm, a phenomenon previously reported in 
Barrett's metaplasia (Jethwa et al., 2008) and ameloblastoma (Siar and Ng, 2014). ZEB1, 
SMA and CD44 protein expression did not differ significantly between lesional LPP and 
healthy control bulges (Supplemental Figure 2).  
 
Cells undergoing EMT within the bulge express the eSC marker Keratin 15+  
Next, we performed dual immuno-fluorescence microscopy of vimentin with the prototypic 
bulge SC marker, keratin 15 (K15) (Purba et al., 2014). This documented that at least some of 
the vimentin-expressing cells in the bulge of lesional LPP HFs represent indeed eSCs (Figure 
1E). These analyses also independently confirmed our previous finding that K15 is markedly 
reduced (Harries et al., 2013). With patient biopsies we are unable to conclusively prove the origin 
of these vimentin/K15 double-positive cells. However, invasion of dermal fibroblasts into the bulge 
epithelium has not been reported outside of malignancy, and we are not aware of any evidence that 
non-malignant, non-transformed human mesenchymal cells (such as dermal fibroblasts) can ever 
express the eSC-associated keratin 15 in situ. Therefore, we conclude that the only plausible 
explanation for vimentin/K15 double-positive cells is that eSCs underwent EMT within the bulge.  
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Thus, our data clearly show that at least some human eSCs in the bulge epithelium of HFs 
affected by LPP undergo EMT, thus potentially contributing to the extensive scarring seen in 
LPP and likely other PCAs. Therefore, future LPP management should also attempt to 
effectively inhibit the EMT of bulge eSCs before it becomes irreversible. Our findings are in 
line with the recent report that EMT also occurs in human HF epithelium in situ during keloid 
formation, as indicated by abnormal vimentin expression (Yan et al., 2015). Thus, it is 
conceivable that anti-EMT therapies developed by studying LPP as a model disease may also 
become applicable to other diseases characterized by excessive scar tissue formation.  
 
EMT can be induced in healthy human HFs ex vivo 
However, given that LPP is an orphan disease (ORPHA:525, http://www.orpha.net), clinical 
material is difficult to obtain, and patients typically seek medical attention only during late-
stage disease (Sinclair, 2016). Therefore, we wondered if it would be possible to 
experimentally mimic the early molecular changes associated with EMT in the bulge of 
microdissected, organ-cultured healthy human HFs (Langan et al., 2015).  
We designed a cocktail of recognized EMT-promoting agents containing; epidermal growth 
factor (EGF), transforming growth factor-1 (TGF-1), interferon- (IFN-), and the 
selective E-cadherin inhibiting peptide SWELYYPLRANL (peptide A) (Segal and Ward, 
2017), and exposed organ-cultured, full-length human anagen VI HFs which had been 
microdissected with their bulge area intact to this “EMT cocktail” (see supplemental methods 
for details).  
Intriguingly, after only 3 days, this rapidly, significantly, and reproducibly reduced E-
cadherin transcript and protein expression in the bulge epithelium of “EMT cocktail”-treated 
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HFs ex vivo, compared to vehicle- treated control HFs (Figure 2A). Vice versa, vimentin and 
SLUG transcript and protein expression were significantly increased (Figure 2), replicating 
the changes observed in the bulge of lesional LPP. Extending the cultures to day 6 did not 
further increase these effects, suggesting that a maximal induction of EMT had occurred. 
Omitting any one of the “EMT cocktails” constituents reduced the potency of EMT induction 
(Supplemental Figure 3).  
To our knowledge, this is the first report of both, experimentally induced EMT in adult 
human eSCs within their physiological SC niche and in a healthy human (mini-)organ ex 
vivo. Given the critical importance of the eSC niche and its surrounding mesenchyme for HF 
development, growth, and survival  (Sennett and Rendl, 2012), this simple, but clinically 
relevant assay opens up new possibilities for interrogating and manipulating the as yet 
obscure (patho-)biology of human eSC that undergo EMT.  
Moreover, as expected from the general EMT literature (Nieto et al., 2016, Pasquier et al., 
2015, Serrano-Gomez et al., 2016, Stone et al., 2016, Zeisberg and Neilson, 2009), our assay 
identifies the suppression of E-cadherin-mediated signaling and stimulation by TGF-ß1, EGF, 
and IFN- as four molecular key signals sufficient to induce EMT in primary human eSCs in 
situ. This is well in line with the fact that TGF-1 is typically overexpressed in fibrotic 
diseases (Walraven et al., 2017) and that IFN- is overexpressed in/around lesional LPP HFs 
(Harries et al., 2013). Therefore, our HF organ culture results encourage one to preferentially 
target in subsequent studies these specific pathways when attempting to therapeutically 
counteract EMT-related HF scarring and loss of eSCs.  
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Pioglitazone stimulates PPAR-γ via downregulation of TGF-, protecting against and 
partially reversing EMT induction  
Next, we explored the utility of our new HF organ culture EMT assay for the identification of 
promising drugs that can counteract EMT in the eSC zone of human HFs. For this, we turned 
to the PPAR-γ agonist, pioglitazone, i.e. a widely prescribed insulin- sensitizing agent 
primarily used for treating type 2 diabetes mellitus (DeFronzo et al., 2011). Pioglitazone 
reportedly can inhibit ocular EMT (Hatanaka et al., 2012). Moreover, compared to healthy 
skin, LPP skin shows a defect in PPAR- expression (Karnik et al., 2009), and PPAR- 
agonists have been advocated as a third line therapy for LPP (Mirmirani and Karnik, 2009). 
Since PPAR- expression in the bulge itself does not differ between lesional and non-lesional 
LPP HFs (Harries et al., 2013), even diseased HFs should still be susceptible to PPAR-  
modulation. HFs treated only with the “EMT cocktail” showed the expected EMT induction 
signature, namely decreased E-cadherin alongside increased vimentin and SLUG expression 
ex vivo. Instead, when pioglitazone (30µM) was administered to the culture medium one day 
before the “EMT cocktail”, E-cadherin and vimentin expression did not significantly differ 
from that of vehicle-treated control HFs (Figure 3A and Supplemental Figure 4). Moreover, 
Slug protein expression was significantly reduced by pioglitazone pretreatment compared to 
EMT-cocktail alone, although it was only partially repressed compared to vehicle treatment. 
The investigated pioglitazone dose was not capable of reversing the molecular EMT 
signature, when pioglitazone was added 72h after experimental EMT induction (Figure 3A). 
 
Epithelial cells grown in vitro readily adopt an EMT-like state (Stone et al., 2016), thus to 
explore the mechanisms by which Pioglitazone might inhibit EMT, we treated isolated hair 
follicle keratinocytes in monolayer culture. Following stimulation with Pioglitazone PPAR- 
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is increased, with a downregulation of TGF-1, SMAD2 and SMAD3 (Figure 3B). This 
effect is blocked by the co-treatment with the PPAR- antagonist GW9662 (Figure 3B). In 
addition, PPAR- stimulation was also enhanced when TGF-B1 expression was suppressed 
via siRNA (Figure 3C). To further confirm this mechanism we assessed paired lesional vs 
uninvolved whole tissue biopsies from LPP patients. We show that TGF-1, SMAD2 and 
SMAD3 are all upregulated, while PPAR- is downregulated (Figure S5), adding further 
support for TGF- signaling as a key mechanism for EMT in LPP, and the potential of 
PPAR- agonism in the treatment of this and perhaps other fibrotic diseases. 
 
PPAR-γ stimulation by N-Acetyl-GED partially reverses EMT signature in normal and 
LPP HFs 
Given that pioglitazone has adverse effects that question its utility for treating hair diseases 
(Ramot et al., 2015), we also investigated the EMT-modulatory activity of N-Acetyl-GED 
(AGED), a topically applicable PPAR- modulator that is undergoing clinical trials in acne 
vulgaris (www.clinicaltrialsregister.eu/ctr-search/trial/2016-000540-33/HU). This showed 
that all three tested concentrations of AGED significantly reduced the number of SLUG+ or 
vimentin+ cells compared to HFs treated with the EMT cocktail alone (Figure 4A and 
Supplemental Figure 6). Remarkably, this was seen when AGED was added either before 
(prevention), or after (rescue) EMT induction, suggesting that AGED may even be capable of 
partially reversing early-stage EMT. However, AGED effects on bulge E-cadherin expression 
were unimpressive (Figure 4A) E-cadherin could not be rescued within the experimental window 
by either Pioglitazone or AGED, suggesting that either the 3 day experimental window was 
insufficient to promote E-cadherin expression, or that additional signals are required to restore E-
cadherin functionality. The lack of a dose dependent response with AGED was surprising 
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though has previously been observed (Ramot et al., 2014). The reason for this might be due 
to measuring indirect effects of PPAR- activation, or variability in the levels of EMT 
induced within each HF.  Finally, to understand whether AGED could reverse EMT in LPP we 
collected fresh biopsy tissue from the lesional site of 2 LPP patients. After 5 days, tissue cultured with 
0.1mM AGED showed a significant improvement  in the expression of E-cadherin and SLUG, whose 
expression patterns tended towards that of healthy skin, while a non-significant trend was observed 
with Vimentin (Figure 4B).  
 
The reduction of experimentally induced EMT in the human bulge ex vivo with pioglitazone 
or AGED treatment demonstrates that our HF assay is well-suited as a screening system for 
identifying candidate drugs that may be repositioned for therapeutically counteracting EMT 
in human eSCs. Also, our results are well in line with evidence that PPAR- agonists 
attenuate experimentally induced fibrosis in other organs (Aoki et al., 2009, Ramot et al., 
2015), possibly through the suppression of TGF- signaling (Hatanaka et al., 2012). AGED is 
of particular interest in this context, since this PPAR- modulator may also protect human HF 
eSCs from apoptosis and stimulates keratin 15 expression in human scalp HF eSCs ex vivo 
(Ramot et al., 2014).  
 
Given that LPP skin shows significantly reduced PPAR- transcription compared to healthy 
human scalp skin (Supplemental Figure S5), LPP patients may be at a (constitutive?) 
disadvantage in suppressing EMT in their HF eSCs, prior to infiltration of CD8+ T cells into 
the bulge (Figure 5). Thus, sufficient PPAR-−mediated signalling may well be critical for 
HF eSC maintenance and homeostasis, namely in individuals predisposed to developing LPP. 
This further encourages one to systematically explore PPAR- modulators as complementary 
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therapeutics in LPP (and other PCAs) alongside immunosuppressive regimen. Reports of 
PPAR-  agonist therapy in LPP are limited to small case series only; “improvement” 
(classified as a reduction in symptoms, diminished signs of inflammation and cessation of 
hair loss progression) was reported in 50-70% cases, although complete remission was seen 
less frequently and scarring was not reversed (Mirmirani and Karnik 2009; Baibergenova and 
Walsh 2012; Mesinkovska, Tellez et al. 2015)(Spring, Spanou et al. 2013).  
Moreover, as Pioglitazone and AGED show slightly different efficiencies at inhibiting 
various EMT target genes, a combination of different PPAR- agonists might be used in 
concert to supress EMT most effectively.  
In summary, our study introduces LPP as a model disease for pathological EMT in human 
adult eSCs, and shows that an EMT signature can be experimentally induced and 
therapeutically manipulated in these human eSCs within their niche, namely by PPAR- 
agonists. 
 
 
 
 
 
 
Materials and Methods 
 
Study approval 
LPP patient and health scalp tissue samples were obtained from the Manchester Skin Health 
Biobank (UK Ethics Committee approved study 14/NW/0185), at the University of 
Manchester, with additional samples from study 14/NW/0342. For experiments with AGED, 
healthy and LPP scalp tissue samples were obtained with ethical approval of the University of 
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Las Palmas of Gran Canaria (CEIH-2014-06) or the University of Münster (2015-602-f-S). 
All samples were taken with informed patient consent.   
Human tissue  
Human scalp skin was obtained with informed consent, with studies performed at the Salford 
Royal NHS Foundation Trust /University of Manchester. Diagnosis of LPP was determined 
via standard clinical and histopathological criteria (Harries and Paus, 2010, Sinclair, 2016). 
Many of the LPP specimens had been diagnostically classified and assessed during our 
previous study (Harries et al., 2013). Lesional specimens were taken from clinically inflamed 
edges of alopecia containing a reduced density of hairs and were fixed in formalin for 
paraffin embedding (FFPE) (see Supplemental Table 2 for clinical features of each patient). 
Paired lesional and non-lesional specimens were also obtained from this cohort and snap-
frozen in liquid nitrogen. Clinically healthy control samples (n =4) were obtained from 
surplus occipital scalp skin of patients undergoing elective hair restoration surgery (mean age 
50 years).  
 
Quantitative RT-PCR  
In order to permit optimal comparisons with the results from our previous study, the same 
RNA samples used previously (Harries et al., 2013) were used in the current study. qRT-PCR 
was performed on a StepOne PlusTM Real-Time PCR system using Taqman gene expression 
assays. Whole tissue biopsies from paired lesion and uninvolved areas from 3 additional 
donors was used to profile TGF- signalling, with RNA isolation and qRT-PCR as previously 
described (Panicker et al., 2012). For details of probes used see Supplemental Table 3.  
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Human hair follicle organ culture  
Serum-free organ culture of human anagen scalp HFs was performed as previously described 
(Langan et al., 2015), from the occipital or temporal scalp of patients undergoing hair 
restoration surgery. Individual full length HFs were dissected from the surrounding tissue or 
microdissected from the tissue and incubated overnight in culture media (Williams E media 
supplemented with Insulin (10g/ml), Hydrocortisone (40ng/ml), L-glutamine (2mM), 
Penicillin (100g/ml) and Streptomycin (100U/ml)). The following day HFs present in 
anagen VI were transferred to media supplemented with either vehicle or a cocktail of agents 
known to promote EMT (TGF-1 (3ng/ml), EGF (10ng/ml), interferon- (500IU/ml)) or to 
inhibit E-cadherin-mediated cell-cell contact (H-SWELYYPLRANL-NH2; Peptide A, 
500nM (Segal and Ward, 2017). HFs were harvested into OCT embedding compound and 
stored at -80°C prior to use.  In co-culture studies, pioglitazone (30M; Enzo Life Sciences) 
or AGED (0.01, 0.1, 1mM; PPM Services S.A.) was added either 24h prior to (prevention) or 
72h following (rescue) addition of the EMT cocktail. 
 
Culture of LPP tissue 
A single 4mm punch was taken from the LPP lesional site in two female donors (44 and 78 
years old). The biopsy was cut into half with each piece of tissue grown in culture media 
(described above). Tissue was dosed with vehicle or 0.1mM AGED on days 1 and 3, with the 
tissue harvested at day 5 and snap frozen in cryomatrix.   
 
Culture of human outer root sheath keratinocyte cells 
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Primary human hair follicle outer root sheath cells were purchased from ScieCell Research 
Labs (Carlsbad, CA) and cultured as previously described (Panicker et al., 2012). Cells at 
passage 3 or 4 were seeded at 0.6x106 cells per well and treated with either 10 M 
Pioglitazone, 10 M Pioglitazone plus 10 M GW9662, or vehicle for 16-24 hours. Data are 
taken from 3 independent experiments and analysed using one way Anova. 
50 M of TGF-1 siRNA was added to ORSK cells for 24 hrs compared to empty vector 
alone (OriGene).  
 
 
Immunohistochemistry and quantitative immunohistomorphometry 
6m sections were used for immunohistochemistry of FFPE and frozen samples. Heat-
induced antigen retrieval (Citrate or Tris-EDTA) was performed as required. For IHC 
protocol summary, see Supplemental Table 4). Immunostaining intensity of the HF bulge 
was assessed by quantitative immunohistomorphometry using NIH image software (“Image 
J”, NIH, Bethesda, Maryland), as previously described (Harries et al., 2013). Only HFs where 
the bulge region could be definitively identified were used for analysis, which for biopsy 
samples this was confirmed by positioning of the arrector pili muscle, while for organ 
cultured HFs the co-localisation with 6 integrin was used to mark the basement membrane. 
For the AGED experiments, Vimentin, SLUG, and E-cadherin immunoreactivity was 
evaluated in 9-12 HFs/donor in 3 independent experiments (3 different donors) for the rescue 
or prevention assay. For this assays, pooled data from 3 donors are presented as Fold increase 
of Mean±SEM. Statistical analysis was performed using Mann-Whitney and p<0.05 as 
regarded as significant.  
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Transmission electron microscopy 
Samples were prefixed with 2.5% glutaraldehyde and 2% paraformaldehyde in 0.1 M 
phosphate buffer and fixed with 1% osmium tetroxide in the same buffer. Samples were then 
dehydrated via ethanol gradient, immersed in propylene oxide, and embedded in resin. 
Ultrathin sections were stained with tannic acid-uranyl acetate solution and lead citrate, and 
observed using the H-7500 apparatus (Hitachi, Japan). 
 
Statistics  
Non-paired samples were compared using two-sample Student’s t-test assuming equal or 
unequal variance after F-test. Human HF organ culture groups were compared using one-way 
ANOVA. For the AGED human HF organ culture, pooled data from 3 donors are presented 
as fold-change compared to vehicle and analyzed by Mann-Whitney test. Data are expressed 
as mean ±SEM; p values of <0.05 were deemed significant. 
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Figure legends 
Figure 1. Evidence of EMT can be identified within the bulge epithelium of LPP hair 
follicles. H&E histochemistry of a healthy human scalp hair follicle (HF) indicating the bulge 
niche (A). Lesional LPP HFs display some cells with a spindled morphology within bulge 
epithelium (B). Transmission electron microscopy reveals that LPP bulge keratinocytes can 
be found with abnormal collagen fibres visible within their cytoplasm (C). Analysis of LPP 
tissue reveals changes in a panel of EMT related markers (D). Co-expression of vimentin 
with the bulge eSC marker keratin 15 is observed (E). Black arrows in (B) denote cells of a 
fibroblast-like morphology. Arrows in (C) indicate intracellular collagen fibres, while 
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arrowheads denote extracellular collagen fibres. Nu = nucleus, Cy = cytoplasm, Mt = 
mitochondria, ECM = extracellular matrix, APM =arrector pili muscle. White arrows in (E) 
identify cells double positive for vimentin and keratin 15 within the bulge, while arrowheads 
mark cells positive for vimentin alone. Boxes indicate areas of higher power magnification, 
dashed lines indicate the basement membrane.  Bar = 50 m (B, E), 833nm (C; upper panel), 
500nm (C; lower panel). 
 
Figure 2. Bulge EMT can be experimentally induced in healthy human HFs ex vivo. HF 
organ cultures were prepared in the presence of an EMT inducing cocktail (IFN-, TGF-, 
EGF, Peptide A; “EMT”) or with vehicle alone as control (Veh). Figures show representative 
immuno-fluorescence images and quantification for E-cadherin (A) (red), vimentin (B) (red), 
and Slug (C) (red). Integrin a6 (green) was used to locate the basement membrane, which 
demarcates the borderline between bulge epithelium and its surrounding mesenchyme. 
Sections were counterstained with DAPI (blue). Data are presented as the mean of 3 
independent experiments with full-length anagen VI scalp HFs from 3 different individuals (3 
hair follicles per donor) +/- SEM, * P<0.05,. Bar = 50 m. Arrows in (B) & (C) indicate 
positively labelled cells.  
 
Figure 3.  PPAR- stimulation by Pioglitazone can partially repress induction of an 
EMT signature, through inhibition of TGF-.  The PPAR- agonist pioglitazone partially 
protected from EMT induction when treated 24hrs prior to the EMT-inducing cocktail, but 
did not reverse EMT when added 72hrs retrospectively (A). qRT-PCR of human outer root 
sheath keratinocyte (ORSK) cells treated with Pioglitazone reveals a suppression of 
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expression of TGF- pathway genes, which is blocked by the PPAR- antagonist GW9662 
(B). PPAR- expression in ORSK cells is stimulated by knockdown of TGF-1 by siRNA 
(C). Data presented as the mean of 3 independent experiments +/- SEM, in A n=3 hair 
follicles per donor. Data in A & B analysed by Anova, while data in C analysed by t test. 
P<0.05, ** P<0.01, *** P<0.001.  
 
Figure 4.  PPAR- stimulation by N-Acetyl-GED can partially rescue from an EMT 
signature, in healthy and LPP HFs.  The PPAR- agonist N-Acetyl-GED (AGED) not only 
protects against experimental EMT induction, but can also rescue SLUG expression to 
normal levels, and partially rescue vimentin expression (A). AGED significantly enhances E-
cadherin expression and significantly inhibits SLUG expression in cultured LPP HFs, with a 
trend towards inhibition of Vimentin (B). Data in A presented as mean values from 3 donors 
(n=6-15 HFs per donor) normalised to untreated hair follicles and represented by a red dotted 
line. Data in B presented as mean values normalized to vehicle control (veh) from 2 donors 
with n=8-18 hair follicles per donor. * P<0.05, ** P<0.01, *** P<0.001. 
 
Figure 5.  Proposed mechanism for lichen planopilaris development. Our available data 
suggest the following scenario:  Inflammation- (T cell-?) induced downregulation of E-
cadherin along with excessive IFN--, TGF-ß1- and EGF-signalling promote pathological 
EMT in bulge eSCs of human scalp HFs, thus contributing to the scarring associated with 
LPP. PPAR- agonists may prevent or even partially reverse this EMT process, besides 
exerting eSC-protective and immunosuppressive functions, if administered early enough. 
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